Involved in lineage commitment of primary hemopoietic progenitors by restricting erythroid formation and enhancing myeloid formation. Interferes with erythropoietin-induced erythroid terminal differentiation by preventing cells from exiting the cell cycle through suppression of CDKN1B/p27Kip1 levels. Suppresses RFWD2/COP1 activity via CSN3 which activates p53 and induces cell cycle arrest. Binds DNA and affects the expression of a number of genes so may function as a transcription factor in the nucleus.
Yoneda-Kato N., Oncogene 12:265-275(1996) [PubMed: 8570204].
Hanissian S.H., Oncogene 23:3700-3707(2004) [PubMed: 15116101].
Yoneda-Kato N., EMBO J. 24:1739-1749(2005) [PubMed: 15861129].